ArticleBMC endocrine disorders2026
Inferior metabolic control in isolated diabetic patients under the context of multimorbidity management: a comparative study.
Article in BMC endocrine disorders, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
purposeTo explore the metabolic control status of patients with type 2 diabetes mellitus (T2DM) with or without hypertension or hyperlipidemia under the management of metabolic management centers (MMC).
methodEligible patients with T2DM from the Yan’an University Affiliated Hospital Branch of the MMC were retrospectively enrolled and categorized into non-hypertensive and hypertensive groups, as well as non-hyperlipidemic and hyperlipidemic groups. Propensity score matching (PSM) was used to balance the baseline confounding variables. Intergroup comparisons of metabolic indicators were conducted and correlation analyses were performed for these indicators.
resultAfter PSM to balance baseline confounding factors, T2DM patients with hypertension or hyperlipidemia showed significantly better control of key metabolic indicators than those without these comorbidities. Specifically, the comorbid groups had lower levels of glycated hemoglobin (HbA1c), postprandial glucose, total cholesterol, and low-density lipoprotein cholesterol (LDL-c). Additionally, the insulin resistance index (HOMA-IR) correlated with triglyceride and high-density lipoprotein cholesterol (HDL-c) levels, further reflecting the metabolic advantages associated with comorbidities under standardized management.
conclusionT2DM patients without hypertension or hyperlipidemia have poorer metabolic control under MMC management, emphasizing the need for tailored management strategies for this “potentially underprioritized group.” CLINICAL TRIAL NUMBER: Not applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.